Next-generation cancer treatment: Patient stratification with immuno-oncology
15 Jun 2020
This video explains how using biomarkers on tissue samples not only provides new insights into the biology of cancer but ultimately enables a new level of patient stratification. This allows the most effective treatment to be used for any given cancer leading to significantly improved outcomes for patients.
About the company
Akoya Biosciences
Akoya Biosciences, 'The Spatial Biology Company', is committed to developing powerful imaging tools to enable scientists and clinical researchers gain a better understanding of complex diseases such as cancer. The company offers the most comprehensive end-to-end solution for high-parameter tissue analysis from discovery through clinical and translational research, enabling more precise therapies for immuno-oncology and other drug development applications. Akoya’s CODEX platform enables the assessment of more than 40 markers and is ideally suited for biomarker discovery. The company’s Phenoptics platform provides the assay robustness and throughput necessary for translational and clinical research required in clinical trials.
Related products
Request Quote for All Products
PhenoImager® Fusion
Akoya BiosciencesThe PhenoImager ® ; Fusion system is a whole-slide, single-cell resolution, ultrafast multispectral imager ideal for standard throughput brightfield and fluorescence imaging applications. This imaging platform can be integrated with the PhenoCycler ® ; system (formerly CODEX ® ) for ultra high-plex spatial discovery at scale.
PhenoImager® HT
Akoya BiosciencesPhenoImager ® HT (formerly Vectra ® Polaris™) is the fastest and most highly cited whole-slide, single-cell resolution imaging platform for spatial phenotyping and the development of spatial signatures. Featuring Akoya’s patented Multispectral Imaging (MSI) and spectral unmixing technologies, this platform can be easily integrated into high-throughput workflows to accommodate projects regardless of your scale.
